In respect of Scheduled formulations, there is no impact on the prices of about 4% formulations, which mainly include formulations related to Immunization Program, Anti-cancer, Oral rehydration salts, Contraceptives etc. In most of the remaining formulations, which account for nearly 16% of total pharmaceutical sector, there is an increase in the prices to the extent of nearly 2.30%.
The Government has fixed the ceiling prices of 851 formulations/ (packs) included in Revised Schedule - I of the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The details have been uploaded on National Pharmaceutical Pricing Authority (NPPA)'s website www.nppaindia.nic.in. The slab-wise reduction in the prices under National List of Essential Medicines, 2015 (NLEM 2015) is as given below:
Slab-wise Percentage reductionwith respect to Maximum Price No. of formulations0<= 5% 2345<=10% 13410<=15% 9815<=20% 9820<=25% 9325<=30% 6530<=35% 4635<=40% 24Above 40% 59Total formulations in NLEM 2015 851
NPPA is effectively monitoring the prices of scheduled as well as non-scheduled medicines under DPCO, 2013 so that these formulations are available to public at ceiling prices notified and increase in price is limited to the provisions of DPCO, 2013. It takes action against companies found overcharging the consumers based on the references received from the State Drugs Controllers/ individuals, samples purchased from the open market, reports from market based data and complaints reported through the grievance redressal websites - 'Pharma Jan Samadhan' and 'Centralized Public Grievance Redress and Monitoring System (CPGRAMS)'. The monitoring of increase in the price of formulations beyond the permissible limit is also done on the basis of market data submitted by All Indian Origin Chemists & Distributors Limited (AIOCD)(Pharma Trac Data) and individual complaints received.
Further, the production and availability of medicines is also regularly monitored by the NPPA mainly through Drugs Control Administration of State Governments. Whenever shortage is reported by the State Drug Controllers or when the matter comes to the notice of NPPA, remedial steps are taken for ensuring availability of drugs by impressing upon manufacturers to rush the stocks to the places of shortage.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
